46
MEDYA
TR
EN
Home
Genel
News Detail
Morning Star
May 31, 2026
|
15:30
Kelonia Therapeutics Presents Updated First-in-Human Data from Phase 1 inMMyCAR Study of KLN-1010 in vivo BCMA CAR-T Therapy at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
...
Full Story at Source
Related News
Here's how Gap's yoga-wear maker Athleta went from must-have to 'generic'
'I have no preexisting conditions': I'm 56, earn $198,000 and want to retire early. Can I afford private healthcare?
Daraxonrasib vs. pancreatic cancer: Experimental pill helped people live longer
Ivonescimab with Chemotherapy Demonstrated a Statistically Significant Overall Survival Benefit Compared to Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China
